Recent News

• 06.04.2026 - The CEO Who Wants to Make Tacrolimus History
• 05.18.2026 - The Greatest Women’s Health Breakthroughs of 2026: New Research That Could Change Your Year
• 05.01.2026 - Biotech Breakthrough
• 04.28.2026 - We fact-checked the hype behind the Eledon Pharmaceuticals Type 1 diabetes treatment
• 04.27.2026 - MAb-based immunosuppressant supports crucial diabetes cell transplants
• 04.21.2026 - Beating transplant challenges
• 04.14.2026 - Transplanting Islet Cells with Piotr Witkowski, MD, PhD
• 04.14.2026 - In Vivo’s 2026 Rising Leaders
• 04.06.2026 - ‘A cure on the horizon’: Are we finally close to ending type 1 diabetes?

Recent Filings

• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.13.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.13.2026 - EX-99.1 EX-99.1
• 05.13.2026 - 8-K Current report
• 05.11.2026 - EFFECT Notice of Effectiveness
• 05.01.2026 - S-3 Registration statement under Securities Act of 1933
• 04.30.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.30.2026 - ARS Annual Report to Security Holders
• 04.30.2026 - DEF 14A Other definitive proxy statements
• 04.27.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors